Back

Glioblastoma-derived extracellular vesicles released after radiation promote cognitive impairment through NFκB-mediated microglial activation

Macias Palacio, S.; Rummel, N.; Campbell, J.; Butterfield, D. A.; Bondada, S.; Wang, C.; Faisal, A. S. M.; Villano, J.; Bauer, B.; St Clair, D.; Chaiswing, L.

2026-06-11 cancer biology
10.64898/2026.06.09.730969 bioRxiv
Show abstract

Glioblastoma (GBM) is the most aggressive primary brain tumor in adults. Cognitive impairment is a common sequela in glioblastoma survivors, yet the underlying mechanisms remain poorly understood. Extracellular vesicles (EVs) derived from glioblastoma are established mediators of intercellular signaling within the tumor microenvironment. Here, we investigated whether GBM-derived EVs released after radiation treatment (RT-EVs) regulate cognitive function. Treatment with RT-EVs was associated with cognitive deficits and neuroinflammatory responses in vivo. In vitro, RT-EVs activated the NF{kappa}B pathway and induced the release of neurotoxic H2O2. Importantly, NF{kappa}B p50 knockdown abolished the H2O2 release previously triggered by RT-EVs, demonstrating mechanistic dependence on NF{kappa}B signaling. Collectively, these findings identify GBM-derived RT-EVs as critical mediators of cognitive impairment through NF{kappa}B-dependent redox imbalance. EV-driven redox dysregulation may therefore represent a therapeutic target to mitigate GBM-associated cognitive dysfunction. Highlights- Radiation induces the release of glioblastoma-derived EVs that are biologically different from those released under non-irradiated conditions. - EVs released from glioblastoma after radiation are sufficient to impair cognition - EVs from irradiated glioblastoma can activate microglia via NF{kappa}B and induce production of neurotoxic H2O2 Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=52 SRC="FIGDIR/small/730969v1_ufig1.gif" ALT="Figure 1"> View larger version (11K): org.highwire.dtl.DTLVardef@8dc45borg.highwire.dtl.DTLVardef@156547forg.highwire.dtl.DTLVardef@c593e0org.highwire.dtl.DTLVardef@16f68f5_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Neuro-Oncology
36 papers in training set
Top 0.1%
27.7%
2
Journal of Extracellular Vesicles
55 papers in training set
Top 0.1%
7.0%
3
Journal of Neuroinflammation
61 papers in training set
Top 0.2%
5.7%
4
Theranostics
37 papers in training set
Top 0.1%
3.7%
5
Clinical Cancer Research
64 papers in training set
Top 0.6%
3.4%
6
Acta Neuropathologica Communications
89 papers in training set
Top 0.8%
2.5%
7
Neoplasia
23 papers in training set
Top 0.2%
2.2%
50% of probability mass above
8
Nature Communications
5641 papers in training set
Top 43%
2.0%
9
International Journal of Radiation Oncology*Biology*Physics
25 papers in training set
Top 0.3%
2.0%
10
Journal for ImmunoTherapy of Cancer
75 papers in training set
Top 1%
1.8%
11
Cell Reports
1498 papers in training set
Top 18%
1.8%
12
Radiotherapy and Oncology
19 papers in training set
Top 0.2%
1.8%
13
Cell Reports Medicine
153 papers in training set
Top 2%
1.6%
14
JCI Insight
277 papers in training set
Top 5%
1.5%
15
Scientific Reports
3612 papers in training set
Top 61%
1.4%
16
Molecular Cancer Therapeutics
40 papers in training set
Top 0.6%
1.4%
17
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 33%
1.2%
18
Cancer Letters
35 papers in training set
Top 0.7%
1.2%
19
eLife
5828 papers in training set
Top 55%
1.2%
20
Cancer Research
130 papers in training set
Top 2%
1.2%
21
Neuro-Oncology Advances
25 papers in training set
Top 0.3%
1.2%
22
Cell Death & Disease
21 papers in training set
Top 0.3%
1.1%
23
Cancer Research Communications
51 papers in training set
Top 1%
1.1%
24
International Journal of Cancer
49 papers in training set
Top 1.0%
1.1%
25
Journal of Neuro-Oncology
10 papers in training set
Top 0.2%
1.1%
26
Advanced Science
286 papers in training set
Top 8%
1.0%
27
Cellular and Molecular Life Sciences
96 papers in training set
Top 2%
0.6%
28
Science Advances
1243 papers in training set
Top 32%
0.6%
29
Frontiers in Immunology
638 papers in training set
Top 10%
0.6%
30
Molecular Oncology
55 papers in training set
Top 1%
0.6%